Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Insmed (DE:IM8N)
FRANKFURT:IM8N
Insmed (IM8N) Stock Price & Analysis
0 Followers
IM8N Stock Chart & Stats
Day’s Range€23.6 - €24
52-Week Range― - ―
Previous Close€23.8
Volume0.00
Average Volume (3M)N/A
Market Cap
$3.52B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 09, 2024EPS Estimate
-€1.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€43.31Price Target Upside83.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Insmed News
Bulls Say, Bears Say
Bulls Say
Drug Portfolio And Market OpportunityINSM has a robust portfolio of drugs with multi-billion dollar market opportunities in respiratory and inflammatory diseases.
Financial Health And Future ProspectsINSM's cash reserves position it well to fund ongoing clinical trials and support its early-stage programs.
Pipeline Drug PotentialUpcoming Phase 3 data for a chronic lung disease drug has strong potential, with a favorable outcome likely to significantly increase the stock value.
Bears Say
Drug Pipeline RiskKey risks include the clinical outcomes of key drugs in the pipeline, which could impact the stock negatively if results are unfavorable.
Financing ConcernsIf Brenso fails, shares might overshoot on the downside due to concerns on runway/financing.
Market CompetitionMerck's Winrevair is anticipated to fundamentally change the PAH landscape, which could affect TPIP's positioning in the market.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
2.17% Other Institutional Investors
97.83% Public Companies and
Individual Investors
IM8N FAQ
What was Insmed’s price range in the past 12 months?
Currently, no data Available
What is Insmed’s market cap?
Currently, no data Available
When is Insmed’s upcoming earnings report date?
Insmed’s upcoming earnings report date is May 09, 2024 which is in 4 days.
How were Insmed’s earnings last quarter?
Insmed released its earnings results on Feb 22, 2024. The company reported -€1.195 earnings per share for the quarter, missing the consensus estimate of -€1.076 by -€0.119.
Is Insmed overvalued?
According to Wall Street analysts Insmed’s price is currently Undervalued.
Does Insmed pay dividends?
Insmed does not currently pay dividends.
What is Insmed’s EPS estimate?
Insmed’s EPS estimate is -€1.15.
How many shares outstanding does Insmed have?
Currently, no data Available
What happened to Insmed’s price movement after its last earnings report?
Insmed reported an EPS of -€1.195 in its last earnings report, missing expectations of -€1.076. Following the earnings report the stock price went down -2.985%.
Which hedge fund is a major shareholder of Insmed?
Among the largest hedge funds holding Insmed’s share is Baker Bros Advisors LP. It holds Insmed’s shares valued at 11M.
---
Insmed Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€43.31 (83.51% Upside)
€43.31 (83.51% Upside)
Blogger Sentiment
Bullish
DE:IM8N Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $629.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
29.04%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-19.72%
Trailing 12-Months
Company Description
Insmed
Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
---
IM8N Company Deck
---
IM8N Earnings Call
Q4 2024
0:00 / 0:00
---
IM8N Stock 12 Months Forecast
Average Price Target
€43.31
▲(83.51% Upside)
Technical Analysis
Insmed
―
Medicinova
―
Karyopharm Therapeutics
―
Crispr Therapeutics AG
―
Corvus Pharmaceuticals
―
Best Analysts Covering IM8N
1 Year
1 Year Success Rate
11/17 ratings generated profit
1 Year Average Return
+20.51%
reiterated a buy rating 2 months ago
Copying Graig Suvannavejh's trades and holding each position for 1 Year would result in 64.71% of your transactions generating a profit, with an average return of +20.51% per trade.
---